IL6 and rheumatoid arthritis: Indeed, antibodies to these molecules have been clinically approved for the treatment of rheumatoid arthritis, a disease that is closely related to periprosthetic osteolysis, namely, anti‐TNF‐α drugs (infliximab, adalimumab, certolizumab, and golimumab)15 and anti‐IL‐6 drug (Tocilizumab).16